WOBURN, Mass.–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/BOD?src=hash" target="_blank"gt;#BODlt;/agt;–Frequency
Therapeutics, a clinical-stage biotechnology company creating a new
class of drugs based on small molecule stimulation of dormant stem cells
within the body which we refer to as Progenitor Cell Activation (PCA),
today announced the addition of Glenn Dubin to the Company’s Board of
Directors. Mr. Dubin, the Principal of Dubin & Co. LP, a private
investment company based in New York, brings three decades of experience
leading global, multi-strategy organizations across a wide range of
industries to Frequency’s Board.
“We are thrilled to welcome Glenn to the Board during this auspicious
time in Frequency’s growth and development,” said Marc Cohen,
Frequency’s Executive Chairman. “Glenn brings broad leadership
experience across a wide variety of industry verticals and will be
tremendously valuable for us as our clinical pipeline and business
opportunities continue to mature.”
Mr. Dubin co-founded Highbridge Capital Management LLC, an alternative
asset management company in 1992. In 2009, Highbridge was acquired by JP
Morgan Asset Management, and Mr. Dubin remained at the helm to oversee
the transition – a transition considered by many to be an example of a
model succession plan. In 2012, Mr. Dubin, along with a prominent group
of investors, acquired Castleton Commodities International LLC (formerly
Louis Dreyfus Highbridge Energy), a global merchant energy company
active in the physical and financial commodity markets and
infrastructure investing. In 2013, Mr. Dubin stepped down as Chairman
and CEO of Highbridge to focus on Dubin & Co. and the founding of
Engineers Gate LP, a proprietary quantitative trading company. Engineers
Gate has committed itself to building a next generation operating and
technology platform for systematic trading strategies across global
liquid markets.
“I am delighted to join the Frequency team and am looking forward to
playing an active role in the further development and expansion of
Frequency’s business operations,” said Mr. Dubin. “Frequency’s PCA
Regeneration technology is truly unique and is poised to make waves
across a multitude of disease indications.”
Mr. Dubin is a founding Board member and former Board Chair of The Robin
Hood Foundation. Since its inception in 1988, Robin Hood has made more
than $2 billion in grants to the most effective poverty-fighting
organizations in New York City by applying investment principles to
charitable giving. He is also a trustee of Mount Sinai Medical Center in
New York, a Board member of the Museum of Modern Art, and is a member of
the Dean’s Executive Committee of the Harvard Kennedy School. He holds a
B.A. in economics from the State University of New York at Stony Brook.
“Frequency continues to bring together world-renowned executives with
extensive expertise in business development,” said David Lucchino,
President, Co-founder and CEO of Frequency. “The addition of Glenn to
our Board will provide sound guidance and deep knowledge to our
executive leadership as we explore new therapeutic and business
opportunities.”
ABOUT PCA REGENERATION
Founded by pioneers in the field of
regenerative medicine and drug delivery technology, Frequency’s
Progenitor Cell Activation (PCA) Regeneration platform uses a
combination of small molecules to stimulate progenitor cells within the
body to repair diseased or damaged tissue. This technology enables
native tissue regeneration without modifying genes or removing cells
from the body. This avoids the potential safety risks of genetic
engineering and the manufacturing challenges of traditional cell
therapy. This approach has been validated both in animal and human cell
models as well as in a human clinical trial with the potential for broad
application across many therapeutic areas.
ABOUT FREQUENCY THERAPEUTICS
Frequency Therapeutics develops
small molecule drugs to stimulate cells in the body to reverse
biological deficits and restore healthy tissue. Through the transitory
activation of these cells, Frequency enables disease modification
without the complexity of genetic engineering. Our ground-breaking
therapy uses a proprietary combination of small-molecule drugs that
induce progenitor cells to multiply and create new cells. While
Frequency’s lead program targets hearing restoration, our PCA
Regeneration platform has the potential to touch upon a wide breadth of
disease indications. www.frequencytx.com.
Contacts
Stefanie Tuck or Kari Watson
MacDougall Biomedical Communications
+1
781-235-3060
frequencytx@macbiocom.com